Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
iPNOTE - Your Virtual IP Paralegal | $1,000,000 | (Oct 29, 2025)
Flamingo(US) | $2,200,000 | (Oct 29, 2025)
CoreStory | $32,000,000 | (Oct 29, 2025)
Cylerity | $4,000,000 | (Oct 29, 2025)
Sweatpals | $12,000,000 | (Oct 29, 2025)
EPIC(US) | $10,000,000 | (Oct 29, 2025)
Wild Moose | $7,000,000 | (Oct 29, 2025)
UPTIQ | $12,000,000 | (Oct 29, 2025)
Spacial | $10,000,000 | (Oct 29, 2025)
Syllo | $30,000,000 | (Oct 29, 2025)
Paygentic | $2,000,000 | (Oct 28, 2025)
WideField Security | $11,300,000 | (Oct 28, 2025)